Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer

about

Suppression of NADPH Oxidase Activity May Slow the Expansion of Osteolytic Bone Metastases Mechanisms of Therapeutic Resistance in Prostate Cancer.Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis.

P2860

Q26738400-D16116B9-492F-430C-8244-0D3E36444507 Q38754316-5AB666C1-44BF-40F8-B68A-D2143E6758C3 Q47864550-D8F9C660-CA53-4CD5-8428-8D5458C2A570

P2860

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer

Item

http://www.wikidata.org/entity/Q26752785

description

2016 nî lūn-bûn

@nan

2016 թուականին հրատարակուած գիտական յօդուած

@hyw

2016 թվականին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer

@ast

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer

@en

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer

@nl

type

Item

label

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer

@ast

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer

@en

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer

@nl

prefLabel

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer

@ast

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer

@en

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer

@nl

P1476

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer

@en

P2093

Joelle El-Amm

http://www.w3.org/2001/XMLSchema#string

P2860

RANK is essential for osteoclast and lymph node development

Cancer statistics, 2015

Bone resorption by osteoclasts

Radioisotopes for the palliation of metastatic bone cancer: a systematic review

RANKL-RANK signaling in osteoclastogenesis and bone disease

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base.

Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.

Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain.

P304

11-19

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3888685

http://www.w3.org/2001/XMLSchema#string

P356

10.4137/CMO.S30751

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jeanny B Aragon-Ching

P577

2016-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27042152

http://www.w3.org/2001/XMLSchema#string

P932

4807885

http://www.w3.org/2001/XMLSchema#string

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer

about

P2860

P2860

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P3181

P356

P407

P433

P478

P50

P577

P698

P932

P3181

P356

P1433

P1476

P2093

P2860

P304

P31

P3181

P356

P407

P433

P478

P50

P577

P698

P932